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ABSTRACT 
Telomerase is expressed in the majority (>85%) of tumours, but has restricted expression in normal 
tissues. Long-term telomerase inhibition in malignant cells results in progressive telomere shortening 
and reduction in cell proliferation. Here we report the synthesis and characterisation of radiolabeled 
oligonucleotides that target the RNA subunit of telomerase, hTR, simultaneously inhibiting enzymatic 
activity and delivering radiation intracellularly. Oligonucleotides complementary (match) and non-
complementary (scramble or mismatch) to hTR were conjugated to diethylenetriaminepentaacetic 
dianhydride (DTPA), allowing radiolabeling with the Auger electron-emitting radionuclide indium-111 
(111In). Match oligonucleotides inhibited telomerase activity with high potency which was not observed 
with scramble or mismatch oligonucleotides. DTPA-conjugation and 111In-labeling did not change 
telomerase inhibition. In telomerase-positive cancer cells, unlabeled match oligonucleotides had no 
effect on survival, however, 111In-labeled match oligonucleotides significantly reduced clonogenic 
survival and upregulated the DNA damage marker JH2AX. Minimal radiotoxicity and DNA damage 
was observed in telomerase-negative cells exposed to 111In-Match oligonucleotides. Match 
oligonucleotides localised in close proximity to nuclear Cajal bodies in telomerase-positive cells. In 
comparison to match oligonucleotides, 111In-Scramble or 111In-Mismatch oligonucleotides 
demonstrated reduced retention and negligible impact on cell survival. This study indicates the 
therapeutic activity of radiolabeled oligonucleotides that specifically target hTR through potent 
telomerase inhibition and DNA damage induction in telomerase-expressing cancer cells, and paves 
way for the development of novel oligonucleotide radiotherapeutics targeting telomerase-positive 
cancers. 
 
Significance: Findings present a novel radiolabeled oligonucleotide for targeting telomerase-positive 
cancer cells that exhibits dual activity by simultaneously inhibiting telomerase and promoting 
radiation-induced genomic DNA damage. 
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INTRODUCTION 
Human telomeres consist of repetitive TTAGGG nucleotide sequences at the end of chromosomal 
DNA. These structures protect chromosomes from fusion, deterioration and recognition by DNA 
damage response proteins. In normal somatic cells, telomeres erode during each cell division as a 
consequence of the inability of unidirectional DNA synthesis to completely replicate the linear 
chromosomes in the so-called end replication problem (1, 2). When telomeres shorten to a critical 
length, cells undergo senescence or apoptosis, limiting the number of possible cell divisions (1, 2).  In 
the case of cancer, cellular processes are activated to maintain telomere length, providing the cell 
with unrestricted cell division potential (3). In the majority of malignancies (>85%), telomere 
maintenance is the result of the upregulation of telomerase, a protein that has a restricted expression 
profile in normal tissue (4). Human telomerase is a ribonucleoprotein minimally composed of human 
telomerase reverse transcriptase (hTERT), a catalytic subunit, and a human telomerase RNA 
component (hTR), a template sequence-containing subunit encoding the telomeric repeats (5). The 
enzyme acts by catalysing the de novo addition of hexanucleotide telomeric repeats to the 
chromosome-ends, resulting in cell immortality (6). In addition, extra-telomeric properties of 
telomerase have also been uncovered. hTERT can influence tumour development, oncogenesis and 
inflammation via NF-κB and Wnt/β-catenin pathways (7). hTR has been shown to protect against 
apoptosis and oxidative stress (8, 9), and to activate DNA-dependent kinase (DNA-PKcs) to 
phosphorylate hnRNPA1, which is critical for capping telomeres (10, 11). 
As a consequence of its differential expression in cancer versus normal tissue and its role in 
the maintenance of the malignant phenotype, telomerase is regarded as an attractive cancer 
therapeutic target and several telomerase-inhibition strategies have been developed. In particular, 
oligonucleotides complementary to the hTR template sequence act as catalytic inhibitors of 
telomerase and have shown promise in pre-clinical investigations (12–14). The use of 
oligonucleotides as therapeutic agents has been potentiated by the modulation of nuclease 
susceptibility, cell permeability and target affinity while oligonucleotide-based inhibitors offer exquisite 
specificity of action and high binding affinity, owing to the necessary formation of specific base-pairing 
during hybridisation (15). One such inhibitor (GRN163L, Imetelstat) is undergoing clinical trials in 
patients with a variety of cancer indications and positive outcomes have been reported in patients with 
essential thrombocytopenia and myelofibrosis (16, 17). Interestingly, it has been demonstrated that 
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hTR inhibition results in chemo- and radiosensitisation (18-22), which is attributed to both telomere 
length-dependent and -independent mechanisms (23).  
Based on these observations, we hypothesised that targeting hTR with a radiolabeled 
complementary oligonucleotide would provide a largely unexplored and potent approach for the 
targeted radiotherapy of telomerase-positive cancer. The localisation of telomerase in the nucleus 
creates an opportunity for targeting with short-range (nm scale) Auger electron-emitting radionuclides, 
such as Indium-111 (111In). High linear energy transfer (LET) Auger electrons are highly toxic when 
emitted in close proximity to DNA, but have little effect outside this range, thereby providing a 
potentially highly selective therapy with a low side-effect profile (24). In this study, we describe the 
design and biological characterisation of 111In-labeled oligonucleotides that target hTR, thereby 
presenting a novel strategy for targeting telomerase-positive tumours by combining selective 
telomerase inhibition and molecular radiotherapy in a single agent. 
 
MATERIALS AND METHODS 
Reagents 
All chemicals were purchased from Sigma-Aldrich, unless otherwise stated. 
 
Cell culture 
MDA-MB-435 (human melanoma), SKBR3 (human breast cancer), U2OS (osteosarcoma) and WI38 
(human fibroblasts) cells were obtained from the American Type Culture Collection (ATCC). The 
MDA-MB-231/H2N human breast cancer cell line was a gift from Dr Robert Kerbel (University of 
Toronto). Cells were maintained in Dulbecco’s Modified Eagle’s Medium supplemented with 10% 
foetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin/glutamate. Cell line authentication 
(STR profiling) confirmed the identity of the cells used in this work. Cells were regularly checked for 
Mycoplasma infection and were not used beyond passage 20. 
 
Oligonucleotide synthesis and labeling 
2’ O-methyl RNA (2’OMeRNA) oligonucleotides, with or without 5’-amino linkers, were synthesised 
and HPLC-purified by Sigma-Aldrich. Sequences: Match 5’-CAGUUAGGGUUAG-3’, Scramble 5’-
GCAGUGUGAUGAU-3’, Mismatch 1 5’-CAGUUACGCUUAG-3’, and Mismatch 2 5’-
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CAGAUACGCUUAG-3’. As a control, phosphorothioate (PS) DNA oligonucleotides were similarly 
obtained. Sequences: PS Match 5’-CAGTTAGGGTTAG-3’, PS Mismatch 5’-CAGTTAGAATTAG-3’ 
(mismatched bases are underlined). 
For diethylenetriaminepentaacetic dianhydride (DTPA) conjugation, oligonucleotides with 5’-
amino linkers were reconstituted in sodium bicarbonate buffer (0.1 M, pH 8.3). DTPA was combined 
with oligonucleotides in 20-fold molar excess and incubated at room temperature (RT) for 60 min. 
Fractions were separated by size exclusion chromatography (SEC) on a P4-column (BioRad) with 
sodium citrate buffer (0.1 M, pH 5). Oligonucleotide concentration was determined by measuring 
absorbance at 260 nm using a NanoDrop spectrometer (Thermo Fisher Scientific). Radiolabeling was 
performed in sodium citrate buffer by the addition of 0.2 MBq of [111In]InCl3 (subsequently referred to 
as 111InCl3) followed by incubation at RT for 60 min. Fractions were separated on a P4-column and 
gamma-counted for 60 seconds using a Wizard scintillation counter (Perkin-Elmer). Oligonucleotides 
were radiolabeled to the desired molar activity and the radiolabeling efficiency determined by instant 
thin layer chromatography (ITLC) in sodium citrate buffer (0.1 M, pH 5).  
Oligonucleotides were linked to Cy3 for confocal microscopy studies. Oligonucleotides with 5’-
amino linkers were reconstituted in sodium bicarbonate buffer (0.1 M, pH 8.3) to a final concentration 
of 220 μM. Monoreactive functional Cy3 dye (GE Healthcare) was reconstituted in DMSO and added 
to the oligonucleotide, before incubation for 60 minutes at RT. Reaction products were separated into 
50 μL PBS fractions using P4 SEC, as before. Fractions were analysed using a NanoDrop  
spectrometer (Thermo Fisher Scientific) at 260 and 550 nm. 
Telomeric repeat amplification protocol  
The telomeric repeat amplification protocol (TRAP) assay (EMD-Millipore) was setup according to 
manufacturer’s instructions, with an optimised PCR cycle (30 °C, 30 min; 36 cycles of 94 °C / 30 sec; 
53.5 °C / 30 seconds; 72 °C / 60 seconds; of 72 °C / 3 minutes), using 200 ng of protein from MDA-
MB-435 cell lysate, unless otherwise stated. For inhibition experiments, inhibitor or control was added 
immediately prior to the telomerase extension step (30 °C, 30 min). Samples were analysed using a 
fluorescence plate reader (Tecan). The determined telomerase activity was normalised to untreated 
control.  
For analysis of 111In-labeled oligonucleotides, the TRAP assay was modified for the 
accommodation of radioactive samples. In this system, DTPA-conjugated oligonucleotides were 
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radiolabeled to a molar activity of 27 MBq/nmol and pre-incubated with cell lysate for 24 hours. 
Radiolabeled inhibitors were combined with MDA-MB-435 lysate at 27 ng/μL protein concentration in 
a total volume of 60 μL. Following incubation for 24 hours to allow for radioactive decay, inhibitor-
enzyme complexes (7.5 μL) were added to 48 μL of TRAP PCR mix to give 200 ng of lysate protein 
and the final concentration of inhibitor as indicated. Data were fitted using fixed-slope non-linear 
regression and compared using an exact-sum-of-squares F-test and subject to one-way ANOVA with 
post hoc Tukey test. 
 
Internalisation of radiolabeled oligonucleotides 
Cells were seeded in a 24-well plate (2 x 104 cells/well). Oligonucleotides were combined with 
Transfast transfection reagent (Tfx) (Promega) according to the manufacturer’s protocol in antibiotic-
free medium to a concentration of 220 nM and incubated for 15 minutes at RT. Cell-medium was 
removed, replaced with transfection complexes and incubated for the indicated time. Following 
incubation, medium was aspirated and retained. Cells were washed twice with PBS, and the washes 
combined with the medium to constitute the free-fraction. Cell membranes were washed using glycine 
buffer (0.1 M, pH 2.5) at 4 °C for 6 min and re-washed with PBS. To lyse the cells, sodium hydroxide 
(0.1 M) was added and plates incubated for 20 min at RT. The internalised fraction was collected and 
combined with two PBS washes. Fractions were counted using a Wizard gamma-counter (Perkin-
Elmer).  
 
Clonogenic assay 
Cells were seeded in a 24-well plate (2 x 104 cells/well). Cells were transfected with 250 μL of  220 
nM oligonucleotide for 2.5 h before addition of 250 μL medium and incubation for a further 24 h. Cells 
were harvested with trypsin (Gibco) following washing in PBS. Harvested cells were counted before 
plating in six-well plates at a density sufficient to give > 50 colonies for counting. Untreated cells were 
typically seeded at 750 cells/well. Colonies were grown for > 7 days, washed in PBS and stained with 
1 % methylene blue (Alfa Aesar) in 50 % methanol (Thermo Fisher Scientific). Colonies containing > 
50 cells were counted. The surviving fraction (SF) was calculated using the plating efficiency (PE) of 
untreated cells. Data were fitted using the linear-quadratic function and curves were compared using 
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an exact-sum-of-squares F-test. Differences between treatment groups were analysed with a two-way 
ANOVA.  
 
Cell viability assay 
WI38 cells were seeded in a 24-well plate (1 x 104 cells/well). Cells were transfected with 250 μL of 
oligonucleotide (220 nM) for 2.5 h before addition of 250 μL medium and incubation for a further 24 h. 
At 24 h, the solution was removed and replaced with fresh medium. After 72 h, 0.5 mg/mL MTT 
(thiazolyl blue tetrazolium bromide) dissolved in serum-free medium was added for 120 minutes and 
the formazan product eluted using DMSO. Absorbance at 540 nm was quantified by plate reader 
(reference wavelength 650 nm) and the relative cell viability of cell populations determined as a 
fraction of mock-treated control. 
 
Confocal microscopy 
Cells were seeded in 8-well chamber slides (Thermo Fisher Scientific) (2 x 104 cells/well). Cells were 
transfected for the indicated time with 220 nM oligonucleotide in 100 μL, with an additional 100 μL of 
medium added after 2.5 h. A 137Cs-irradiator was used to deliver 4 Gy of J-radiation to induce JH2AX 
foci, as a positive control for staining. Irradiated cells were incubated at 37 °C for 1 h to allow for foci 
induction. Immunostaining (anti-JH2AX 50-636-KC, Millipore and anti-coilin ab87913, Abcam) and 
confocal image acquisitions were performed as described previously (25). Intranuclear DNA damge 
foci were counted manually in > 100 cells per treatment. Nuclear Cy3 mean intensity was quantified 
from > 50 cells per treatment. Groups were compared by one-way ANOVA with a post hoc Tukey test. 
Images represent several fields of view acquired using a 40x/1.2 or 63x/1.4 objective lens, with 4x 
digital zoom.   
 
Statistical analyses 
Data were plotted as the mean ± standard deviation (SD) of the stated number of replicates, unless 
otherwise indicated. Statistical significance was determined using Graphpad Prism 6.03 software and 
is indicated as follows: * P < 0.05; ** P < 0.01; *** P < 0.001 (two-sided). 
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RESULTS 
Synthesis and stability of 111In-labeled oligonucleotides 
2’OMeRNA oligonucleotides were selected based on their resistance to nucleases and serum stability 
(26). Amino-modified 2’OMeRNA oligonucleotides containing a sequence complementary to the 
template region of hTR were conjugated to DTPA to enable subsequent labeling with 111In (Figure 1). 
The region of complementarity between the Match oligonucleotide and hTR is depicted in Table 1, 
which despite some overlap is distinct from the GRN163L site. To ensure sequence-specificity, 
several non-complementary control oligonucleotides (Mismatch 1, Mismatch 2, Scramble) were 
generated and labeled. Oligonucleotides were purified (or confirmed pure) by HPLC and DTPA 
conjugation was confirmed by mass spectrometry (Supplementary Figure S1), and the conjugation 
reaction products were diagnostically radiolabeled (0.2 MBq) before separation by SEC. Analysis of 
the reaction products by gamma-counting demonstrated the elution of two distinct radiopeaks, at 700 
μL (peak 1) and 1400 μL (peak 2) (Figure 2A). Unreacted oligonucleotide was found to elute at 700 
μL by absorbance measurement at 260 nm, and radiolabeled, unreacted DTPA at 1400 μL by 
gamma-counting. Reinjection of the fractions constituting peak 1 on a second SEC column verified 
the presence of a single radiospecies (Figure 2B). As expected, both the amino-modification and 
conjugation of DTPA were found to be necessary for oligonucleotide radiolabeling (Supplementary 
Figure S2).  
To test the stability of the radiolabeled construct, the SEC profile was analysed following 
incubation for 0 or 24 hours. A single radiopeak was observed for both time points (Figure 2C). This 
peak accounted for 92 and 94% of the radioactivity at 0 and 24 hours respectively, determined by 
area under the curve analysis. These results indicated the short-range Auger electrons do not induce 
significant autoradiolysis of oligonucleotide constructs over this time period. High radiolabeling 
efficiency (>90%) was confirmed by ITLC and molar activities up to 27 MBq/nmol were employed for 
subsequent in vitro experiments. 
 
hTR-targeted 111In-labeled oligonucleotides inhibit telomerase activity  
To assess telomerase inhibition by 111In-labeled oligonucleotides, relative telomerase activity was 
determined by a polymerase chain reaction (PCR) based telomeric repeat amplification protocol 
(TRAP) assay in a panel of cancer cell lines. MDA-MB-435 melanoma cells were found to have the 
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highest telomerase activity, with MDA-MB-231/H2N and SKBR3 breast cancer cells expressing 86.3 ± 
0.5 and 42.6 ± 0.4 % of that activity, respectively (Figure 3A). The osteosarcoma cell line, U2OS, was 
found to lack detectable telomerase activity in the TRAP assay, as described previously (27).  
In each cell line, the effect of non-radiolabeled 2’OMeRNA Match oligonucleotide on 
telomerase activity was tested immediately following addition of the construct. Following normalisation 
to untreated control, inhibition of 75, 74 and 72 % was recorded in MDA-MB-435, MDA-MB-231/H2N 
and SKBR3 lysates incubated with Match oligonucleotide at a concentration of 300 nM, respectively 
(Figure 3A). In contrast, Scramble showed no inhibitory activity. The amplification of a pre-elongated 
control substrate, TSR8, was not affected by Match (Supplementary Figure S3), confirming inhibition 
was occurring during telomerase-dependent substrate elongation (28). Further characterisation 
showed that Match inhibited the telomerase activity of MDA-MB-435 lysate in a dose-dependent 
manner with maximum inhibition of 91% at a concentration of 1 μM and an IC50 of 147.4 nM (95% CI: 
91.1–238.3 nM) (Figure 3B). DTPA-conjugation did not significantly alter the IC50 (101.4 nM, 95% CI: 
75.9–135.6 nM) of Match (P > 0.05) (Figure 3C). Furthermore, in a TRAP assay modified for inclusion 
of radioactive samples, no difference in inhibitory potency was observed following radiolabeling with 
111In (Figure 3D). In this modified assay where, as reported previously, pre-incubation with inhibitor 
leads to a perceived increase in potency (29), the IC50 values were found to be 19.6 nM (95% CI: 
11.5–33.3 nM) for 111In-DTPA-Match (subsequently referred to as 111In-Match) and 11.5 nM (95% CI: 
7.7–17.2 nM) for DTPA-Match (P > 0.05). Inhibition of > 96% was achieved with 111In-Match at a 
concentration of 1 µM. The IC50 of Match recorded in the modified TRAP assay was in agreement with 
previously published data, particularly where pre-incubation was explicitly employed (30). In all cases, 
disruption of oligonucleotide complementarity to hTR (Scramble, Mismatch 1, Mismatch 2) abrogated 
inhibitory activity, irrespective of modification with DTPA (Figure 3B, C, Supplementary Figure S4). 
Importantly, radiolabeling did not confer inhibitory capability on control oligonucleotides, with 111In-
DTPA-Scramble (subsequently referred to as 111In-Scramble) lacking inhibitory activity (Figure 3D), 
confirming the preservation of sequence-specific telomerase inhibition.  
To generalise these findings using an alternative oligonucleotide chemistry, we employed 
phosphorothioate (PS) DNA oligonucleotides as an additional control (29, 31). However, PS 
oligonucleotides were found to inhibit telomerase in a sequence-independent fashion (Supplementary 
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Figure S5) and so were unsuitable for therapeutic development. This finding is in agreement with 
published work (29, 32). 
 
Delivery of 111In-labeled oligonucleotides to cancer cells  
To facilitate in vitro cellular characterisation, 111In-Match and 111In-Scramble were introduced into 
cancer cells using liposomal transfection reagents. For each cell line, the transfection conditions were 
optimised to approximately equalise the peak delivery of 111In-Match and 111In-Scramble. Examining 
the uptake of oligonucleotides over a 24 h time period, maximum internalisation occurred after 
approximately 4 hours of treatment in MDA-MB-435, U2OS, SKBR3, and MDA-MB-231/H2N cells 
(Figure 4A-D). The peak uptake of 111In-Match achieved was 8.9 ± 1.6, 6.1 ± 0.1, 10.8 ± 1.1 and 6.8 ± 
0.3 % of total administered radioactivity in MDA-MB-435, U2OS, SKBR3, and MDA-MB-231/H2N 
cells, respectively. Interestingly, while the maximum uptake for cell lines was comparable, 111In-Match 
was retained to a far greater extent than 111In-Scramble in the telomerase-positive cell lines (Figure 
4A, C, D); an effect not apparent in telomerase-negative U2OS cells where both sequences 
demonstrated comparable temporal uptake profiles (Figure 4B).  
 
hTR-targeted oligonucleotides enter the nucleus and associate with Cajal bodies 
As telomerase is predominantly localised to the nucleus (1) and Auger electron-emitting radionuclides 
exert their therapeutic effects most effectively when in close proximity to DNA, the subcellular 
localisation of the oligonucleotides was investigated using fluorophore-labeled constructs in MDA-MB-
435 cells. Cy3-labeled oligonucleotides were synthesised and purified by SEC (Supplementary Figure 
S6). Following transfection for 2.5 hours, a robust Cy3 signal was observed primarily in the cytoplasm 
of cells treated with Cy3-Match or Cy3-Scramble oligonucleotides (Figure 4E). In contrast, 24 hours 
after treatment, Cy3-Match oligonucleotides were retained, with a focal nuclear distribution apparent 
in approximately 30% of cells, while Cy3-Scramble treated cells showed a substantial decrease in 
signal intensity, which remained predominantly cytoplasmic (Figure 4E). Consistent with the uptake of 
radiolabeled oligonucleotides, a reduced signal was recorded in cells treated with label alone (Cy3), 
transfected unlabeled oligonucleotides or non-transfected Cy3-oligonucleotides (Supplementary 
Figure S7). Quantification of the oligonucleotide-Cy3 signal confirmed the preferential nuclear 
retention of Match over Scramble constructs after 24 hours (Supplementary Figure S8). 
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Previous studies have reported that hTR localises to subnuclear Cajal bodies during 
telomerase biosynthesis (33). Importantly, the punctate nuclear oligonucleotide signal that was 
observed in cells incubated with Cy3-Match for 24 hours was found to associate with the periphery of 
coilin, a protein marker of Cajal bodies (Figure 4E) (34). Such an association was absent in 
telomerase-negative U2OS cells (Supplementary Figure S9). These findings suggest telomerase-
targeted oligonucleotides localise to and are retained at the nuclear sites of telomerase assembly. 
 
hTR-targeted 111In-labeled oligonucleotides reduce the survival of telomerase-positive cancer 
cells 
Next, the potential of 111In-Match to selectively reduce the survival of telomerase-positive cancer cells 
was assessed by clonogenic assay. MDA-MB-435 and U2OS cell lines were employed as 
telomerase-positive and telomerase-negative cells, respectively, while treatment with 111In-labeled 
non-complementary Scramble or Mismatch oligonucleotides were included to provide an indication of 
sequence-specificity. Transfection conditions were optimised to provide comparable levels of cellular 
uptake for each individual oligonucleotide; approximately 5-10% internalised radioactivity 
(Supplementary Figure S10).  
Following normalisation to untreated control, the non-radiolabeled Match oligonucleotide (i.e. 
0 MBq/nmol) was shown to have no effect on the survival of cancer cells (SF >0.8, Figure 5), a result 
in line with the notion that long-term treatment with existing telomerase inhibitors is necessary to lead 
to telomere erosion sufficient for therapeutic effect (1). This finding was confirmed in MDA-MB-435 
cells treated with different concentrations of radiolabeled and non-labeled oligonucleotide 
(Supplementary Figure S11). A significant effect on clonogenic survival was observed only following 
treatment with radiolabeled Match (27 MBq/nmol), with non-labeled Match showing no therapeutic 
activity over this timeframe.  
As shown in Figure 5A, 111In-Match caused a significant reduction in the clonogenic survival of 
telomerase-positive MDA-MB-435 cells in an 111In-dependent manner, where treatment with the 
highest molar activity (27 MBq/nmol) resulted in a surviving fraction (SF) of 0.14 ± 0.03. In contrast, 
111In-Scramble, 111In-Mismatch 1 and 111In-Mismatch 2 sequences had minimal impact on MDA-MB-
435 survival even at high molar activities (SF >0.7 at 27 MBq/nmol). Likewise, 111InCl3 in the presence 
of transfection agent demonstrated no therapeutic activity. Importantly, 111In-Match did not 
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significantly reduce the survival of telomerase-negative U2OS cells, with SF of 0.73 ± 0.16 at the 
maximum molar activity of 27 MBq/nmol (Figure 5B) but exhibited therapeutic activity towards two 
additional telomerase-positive cancer cell lines, SKBR3 and MDA-MB-231/H2N (Figure 5C, D). 111In-
Match in the absence of liposomal transfection reagent failed to significantly reduce clonogenic 
survival at the equivalent levels of radioactivity, confirming the requirement for intracellular delivery of 
111In for therapeutic activity (Supplementary Figure S12).  
The potential for off-target toxicity of these novel radiopharmaceuticals was further 
investigated by measurement of the viability of treated normal fibroblasts. These cells cannot be 
analysed by clonogenic assay as they do not form colonies. In WI38 cells, shown to lack telomerase 
activity and exhibiting similar uptake of transfected radiopharmaceuticals (Supplementary Figure 
S13), oligonucleotides radiolabeled to 27 MBq/nmol had minimal effect on cell viability (Figure 5E). 
Furthermore, the modest reduction in viability occurred in an oligonucleotide sequence-independent 
manner, indicating a minimal and non-specific effect on normal cells.  
Long-term telomerase inhibition is known to induce downregulation of hTERT and associated 
downstream cellular effects, for example those leading to altered regulation of the pro-apoptotic 
pathway (35). However, in the short timescale necessary for reduction in clonogenic survival following 
treatment with radiolabeled oligonucleotides, no effect on hTERT expression was observed 
(Supplementary Figure S14). These results indicate that hTR-targeted radiolabeled oligonucleotides 
induce rapid 111In-mediated radiotoxicity selectively towards telomerase-positive cancer cells. 
 
hTR-targeted 111In-labeled oligonucleotides induce DNA damage specifically in telomerase-
positive cancer cells 
To further explore the preferential activity of 111In-labeled oligonucleotides towards telomerase-
positive cancer cells, the upregulation of JH2AX was investigated. JH2AX is a protein involved in the 
recruitment of DNA damage repair factors and is a surrogate marker of DNA double-strand breaks 
(36). In MDA-MB-435 cells, a molar activity-dependent increase in JH2AX foci number was observed 
following treatment with 111In-Match (Figure 6A, B). Treatment with Match labeled to 0, 9, 18 and 27 
MBq/nmol led to upregulation of JH2AX to 3.1 ± 3.1, 7.4 ± 5.3, 12.5 ± 6.5, and 12.7 ± 6.9 foci per 
nuclear confocal plane (NCP), respectively. In each case, the number of foci was significantly higher 
than in cells treated with Tfx alone (3.0 ± 3.3 foci/NCP) and Tfx + 111InCl3 (3.1 ± 2.5 foci/NCP). 
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Notably, the effect of 111In-Scramble labeled to 27 MBq/nmol (3.6 ± 3.4 foci/NCP) was not significantly 
different from control groups, confirming the sequence-specific effect of 111In-Match.  
In contrast, in telomerase-negative U2OS cells, upregulation of JH2AX foci number was not 
oligonucleotide-sequence dependent (Figure 6A, B) and both 111In-Match and 111In-Scramble 
upregulated JH2AX foci number to a modest extent compared to controls but there was no statistically 
significant difference between the two constructs, and no apparent dependency on molar activity 
(111In-Match: 6.1 ± 5.6, 6.1 ± 6, 7.2 ± 6 foci/NCP for 9, 18, and 27 MBq/nmol; 111In-Scramble: 8.2 ± 8.3 
foci/NCP for 27 MBq/nmol and Tfx and Tfx+111InCl3: 2.0 ± 2.9 and 2.7 ± 3.3 foci/NCP). It was 
observed that for 111In-Scramble (27 MBq/nmol) and 4Gy J-radiation there were statistically 
significantly more foci in U2OS than in MDA-MB-435 cells. We speculate that this may indicate 
greater DNA repair capacity in MDA-MB-435 compared to U2OS. Despite this, importantly, the 
induction of JH2AX foci by 111In-Match labeled to specific activities above 9 MBq/nmol was statistically 
significantly greater in MDA-MB-435 than in U2OS cells (P<0.001). The modest upregulation in foci 
number in U2OS cells, coupled to the lack of therapeutic activity of the oligonucleotides in these cells, 
likely reflects the non-specific, sublethal induction of DNA damage following internalisation of 
radiolabeled oligonucleotides. In U2OS cells, unlabeled Match and Scramble did not elicit a significant 
effect (2.6 ± 3.8 and 5.5 ± 5.7 foci/NCP, respectively). Together, these results are consistent with a 
telomerase- and 111In-dependent mechanism of DNA damage induction in telomerase-positive cancer 
cells.  
 
DISCUSSION 
Since the original discovery of telomerase and the observation that it is expressed abundantly in 
malignant compared to normal cells, telomerase inhibition has been intensively investigated as an 
anticancer strategy, including in combination with external beam radiation or chemotherapy. It has 
been demonstrated that telomere shortening caused by down-regulation of telomerase results in 
radiosensitisation (18-23, 37-39), and, conversely, that increased telomerase expression is linked to 
apoptosis resistance and enhanced DNA repair (7). Telomerase protects aneuploid cells against 
replication stress, and promotes genomic stability in cancer cells (40, 41). Moreover, oxidative DNA 
damage, which is a major determinant of radiation toxicity, stimulates telomerase activity (42). We 
have shown previously that targeting hTERT with radiolabeled small molecule inhibitors is a viable 
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anticancer strategy in which telomerase inhibition is achieved synchronously with delivery of a high 
radiation dose (43). Together, these findings provide a strong rationale for combining hTR inhibition 
with molecular radiotherapy for the treatment of neoplastic disease. Although the metal chelator 
DTPA has been shown to facilitate the therapeutic labeling of a wide range of biomolecules with the 
Auger electron-emitting radionuclide, 111In (44), the use of radiolabeled oligonucleotides has not been 
explored in detail. Yet oligonucleotide-based inhibitors offer high binding affinities and specificity 
which, if combined with the radiotoxicity of short-range emitters such as 111In, have the potential to 
generate gene-targeted radiotherapeutics. This concept was proposed by Neumann and co-workers, 
who examined sequence-specific triplex-forming oligonucleotides to carry 125I for this purpose (45, 
46). The use of modified nucleic acids confers improved characteristics on therapeutic 
oligonucleotides. However, for therapeutic development, the selection of alternative chemistry must 
be carefully coordinated with the application. This necessitates the inclusion of stringent experimental 
controls, as exemplified by sequence-independent inhibition of telomerase activity mediated by PS 
oligonucleotides reported here and previously (32).  
We demonstrate that DTPA-conjugation to the 5’-end of 2’OMe-modified oligonucleotides 
results in site-specific 111In-labeling to high molar activity (27 MBq/nmol). An oligonucleotide 
complementary to the template region of hTR inhibited telomerase activity in a sequence- and 
concentration-dependent manner, and inhibitory potency was not compromised by DTPA-conjugation 
or 111In-labeling. Upon cellular delivery, oligonucleotides targeted to hTR were retained in telomerase-
positive cancer cells to a greater extent than the non-targeting control, while clonogenic assay data 
clearly showed a sequence-specific and dose-dependent effect of radiolabeled oligonucleotides on 
telomerase-positive cell survival. The rapid radiation-dependent loss of clonogenic survival 
demonstrated here offers a marked advantage over existing strategies reliant solely on inhibition of 
telomerase, which require long-term treatment for therapeutic effect (1). Crucially, telomerase-
targeted radiolabeled oligonucleotides had little effect on the survival of telomerase-negative 
osteosarcoma cells and normal fibroblasts, despite internalisation occurring to a similar extent as in 
telomerase-positive cell lines. The normal fibroblast cell line, WI38, has low expression of hTR (47), 
and this is a possible explanation for its resistance to 111In-Match. These observations suggest a 
therapeutic window for the selective targeting of telomerase-positive cancer over normal tissue. At the 
activities assayed, a small fraction of cells survived treatment with the radiolabeled construct, possibly 
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due to the stochastic nature of radioactive decay and the short range of Auger electrons, the 
existence of a radioresistant subpopulation of cells, or a failure of delivery. Use of alternative 
radionuclides and development of an efficient in vivo delivery system will be of future importance to 
address such questions.  
Importantly, sub-cellular localisation studies revealed that 24 hours after treatment the non-
hTR targeting oligonucleotides remained mainly cytoplasmic, whereas oligonucleotides 
complementary to hTR were found within the nucleus of MDA-MB-435 cells in distinct foci in close 
proximity to Cajal bodies. In agreement with our findings, the nuclear localisation of fluorophore-
labeled 2’OMeRNA (48) and peptide nucleic acid (PNA) oligonucleotide telomerase inhibitors, has 
been reported previously in cancer and immortalised cells (49, 50). Furthermore, unassigned 
intranuclear foci were observed in a subset of cells (48, 49). The current study shows, for the first 
time, that oligonucleotide telomerase inhibitors accumulate in close association with nuclear Cajal 
bodies. Fluorescence in situ hybridisation staining for the RNA component of telomerase, performed 
post-fixation, revealed a cell cycle-dependent peripheral association between hTR and Cajal bodies 
(51, 52). This cell cycle-dependency likely explains the presence of oligonucleotide foci in only a 
proportion, about 30%, of cells in this study. From the perspective of the radiolabeled hTR 
oligonucleotides, the reported intranuclear accumulation is suggestive of specific target engagement, 
whilst also having the potential to localise the constructs in proximity to DNA and so maximise the 
effects of short-range Auger electron molecular radiotherapy.   
Taken together, these findings demonstrate that the enhanced retention and nuclear 
localisation of radiolabeled oligonucleotides targeted to hTR results in a telomerase-dependent 
cytotoxic induction of DNA double-strand breaks by 111In. In addition, the role of telomerase in the 
DNA damage response and genomic stability offers the opportunity for simultaneous therapeutic 
exploitation of the reported interaction between telomerase inhibition and ionising radiation. It is also 
possible that perturbation of hTR function by 111In-Match results in inhibition of DNA-PKcs, a 
phenomenon that has been reported by others (10). DNA-PK plays a central role in non-homologous 
end joining (NHEJ), the major pathway for repair of ionising radiation-induced DNA double-strand 
breaks in human cells. Therefore, through its inhibition of hTR and, perhaps DNA-PKcs, 111In-Match 
may be impeding the repair of DNA lesions that it is itself causing.  
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This work supplements the emerging potential of Auger electron-emitting oligonucleotides as 
molecular radiotherapeutic agents (45, 53, 54). The intrinsic characteristics of oligonucleotide 
biotherapeutics, including high affinity and specificity of binding and intermediate molecular weight, 
offer therapeutic advantages over existing approaches. However, a recognised challenge of 
therapeutic oligonucleotides is that of effective drug delivery (55) and our current studies are aimed at 
developing nanoparticulate solutions for cancer cell-specific delivery of telomerase-targeted radio-
oligonucleotides. 
In conclusion, we report for the first time the development of an hTR subunit-targeting nucleic 
acid radiopharmaceutical for the selective treatment of cancer. The positive results of 111In-Match in 
telomerase inhibition and clonogenic survival studies provide a strong incentive for further 
development of telomerase-targeted molecular radiotherapy. 
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Table 1. 2’O-MeRNA oligonucleotide sequences. The template region of hTR is shown in bold and 
mismatched bases are underlined. For reference, the sequence of GRN163L (Imetelstat) is also 
shown. 
 
Oligonucleotide Sequence 5'-3' Modification 5'-end 
hTR template (3’-5’) GUCAAUCCCAAUCUGUU - - 
GRN163L 
                   
TAGGGTTAGACAA - - 
    
Match CAGUUAGGGUUAG 2'OMeRNA Amine (AmC6) 
Mismatch 1 CAGUUACGCUUAG 2'OMeRNA Amine (AmC6) 
Mismatch 2 CAGAUACGCUUAG 2'OMeRNA Amine (AmC6) 
Scramble GCAGUGUGAUGAU 2'OMeRNA Amine (AmC6) 
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FIGURE LEGENDS 
 
Figure 1. Preparation of radiolabeled oligonucleotides. 
Amino-modified 2’OMeRNA oligonucleotides of sequence complementary (Match) and non-
complementary (Scramble, Mismatch) to hTR were conjugated to the chelator DTPA, which allowed 
for site-specific radiolabeling with Auger electron-emitting 111In. 
 
Figure 2. Synthesis and stability of radiolabeled oligonucleotides. 
(A) Oligonucleotides modified with a 5’-amino-linker were reacted with cyclic DTPA, radiolabeled with 
0.2 MBq of 111In and separated by SEC. Peak 1 represents radiolabeled oligonucleotides, peak 2 
unreacted DTPA. (B) SEC of peak 1. A single peak represents the existence of a single radiospecies. 
(C) Oligonucleotides were radiolabeled to 27 MBq/nmol and subjected to SEC immediately (92%) or 
after 24 hours (94%) to assess radiolysis of the construct. CPM – counts per minute. 
 
Figure 3. Oligonucleotides inhibit telomerase activity in a sequence-dependent manner. 
(A) Telomerase activity was assayed in MDA-MB-435, MDA-MB-231/H2N, SKBR3 and U2OS cell 
lysate following treatment with 300 nM Match or Scramble oligonucleotide. Data were compared using 
one-way ANOVA with post hoc Tukey test. (B) Telomerase activity of MDA-MB-435 cell lysate after 
treatment with increasing concentration of Match, Mismatch 1, Mismatch 2, and Scramble 
oligonucleotides. (C) Telomerase activity of MDA-MB-435 cell lysate after treatment with increasing 
concentration of Match and Scramble oligonucleotides following DTPA-conjugation. (D) Telomerase 
activity of MDA-MB-435 cell lysate after pre-incubation with 111In-DTPA-Match and 111In-DTPA-
Scramble (27 MBq/nmol) in the modified TRAP assay. Data were fitted using fixed-sloped non-linear 
regression and compared by F-test. ** P < 0.01, * P < 0.05. n=2, data represents three independent 
repeat experiments.  
 
Figure 4. Cellular uptake and subcellular distribution of hTR-targeting oligonucleotides. 
(A-D) 250 μL of 111In-oligonucleotides (220 nM, 3.6 MBq/nmol) or 111InCl3 were combined with 
transfection reagent and incubated with (A) MDA-MB-435, (B) U2OS, (C) SKBR3 and (D) MDA-MB-
231/H2N cells for the indicated time. Cells were washed and lysed, and the proportion of internalised 
Research. 
on September 2, 2019. © 2019 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 16, 2019; DOI: 10.1158/0008-5472.CAN-18-3594 
25 
 
radioactivity determined by gamma-counting. n=6, data from three independent repeat experiments. 
(E) Subcellular localisation of fluorophore-labeled oligonucleotide inhibitors of telomerase in MDA-MB-
435 cells. Cy3-labeled Match and Scramble oligonucleotides (220 nM) were transfected into MDA-
MB-435 cells for 2.5 or 24 hours before fixation. Cells were counterstained for the Cajal body protein 
coilin, and DNA (DAPI). Images represent data from three independent repeat experiments. Scale bar 
40 Pm. 
 
Figure 5. Radiolabeled oligonucleotide inhibitors of telomerase reduce clonogenic survival in a 
specific manner. 
Oligonucleotides (220 nM in 250 μL) were radiolabeled to the indicated molar activity and transfected 
into (A) MDA-MB-435, (B) U2OS, (C) SKBR3 and (D) MDA-MB-231/H2N cells for 24 hours before 
plating for colony formation in the clonogenic assay. Colonies of > 50 cells were counted and the 
surviving fraction (SF) calculated. (E) Normal fibroblasts (WI38) were transfected with 
oligonucleotides (220 nM in 250 μL) radiolabeled to the indicated molar activity for 24 hours and cell 
viability determined 72 hours later. Data were normalised to untreated control. Treatment groups were 
compared using two-way ANOVA and F-test of linear quadratic fitting. *** P < 0.001, n=6, data from at 
least two independent repeat experiments. 
 
Figure 6. JH2AX-induction in MDA-MB-435 and U2OS cell lines following treatment with radiolabeled 
oligonucleotides. 
(A) MDA-MB-435 and U2OS cell lines were treated with radiolabeled oligonucleotides for 6 hours 
before fixation and staining for JH2AX. For quantification, foci contained within a single confocal plane 
of > 100 nuclei were counted. (B) Confocal microscopy images of MDA-MB-435 and U2OS cells 
treated with oligonucleotides/controls. Cells were stained for JH2AX and DNA (DAPI). J-radiation (4 
Gy) was used as a positive control for JH2AX staining. The number of JH2AX foci is statistically 
significantly greater in MDA-MB-435 cells following treatment with 111In-Match versus 111In-Scramble 
at 27 MBq/nmol (dashed line). Significant differences in the induction of JH2AX foci between cell lines 
treated with each construct and 4 Gy are indicated by blue lines. Scale bar 10 μm. Tfx - transfection 
reagent. Groups were compared using one-way ANOVA with post hoc Tukey test. *** P<0.001, ns - 
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not significant. n>100, data from three independent repeat experiments. Line and box represent 
median and 25-75th percentile, respectively. Whiskers represent the 5-95th percentile. 
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